TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Patient Portal Intervention to Address Diabetes Care Gaps

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Established patient at participating primary care clinic~* Type 1 or 2 diabetes mellitus~* Able to speak and read in English~* Age 18 to 75 years old~* Mobile device (smartphone or tablet) with internet access~* Active MHAV account and willing and able to use the MHAV native app on a mobile device~* Due (based on evidence-based guidelines) for any of the following: hemoglobin A1C, urine microalbumin, diabetes eye exam, and/or pneumococcal vaccination.~Exclusion Criteria:~* Known cognitive deficits or functional impairment preventing the use of a mobile device~* Pregnant or planning to become pregnant during the study period~* Severe difficulty seeing~* Severe difficulty hearing~* Medical condition that make it hard for people to understand what they are saying

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Participants will have access to a new feature within an established patient portal native app on mobile devices. The new feature aims to address diabetes care gaps.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. acute ischemic stroke confirmed by diffusion weighted imaging~2. transient ischemic attack (TIA) within 7 days~Exclusion Criteria:~1. there is intracranial hemorrhage on imaging study~2. patients is previously taking antiplatelets, vitamin K antagonists, factor Xa antagonists, or chronic treatment with systemic steroidal and non-steroidal anti-inflammatory drugs~3. patients who received fibrinolytics within the previous 48 hours~4. cognitive impairment interfering with the possibility of obtaining informed consent~5. pregnancy~6. participation in another pharmacological study~7. peptic ulcer disease or hematological abnormality~8. initial modified Barthel index \<30 points~9. liver function tests exceeding a 2-fold upper range value.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cilostazol group (Type: EXPERIMENTAL): aspirin placebo daily and 100 mg cilostazol twice daily
- aspirin group (Type: ACTIVE_COMPARATOR): 100 mg aspirin daily and cilostazol placebo twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Exercise Training on Pain and Brain Function in Gulf War Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veteran of the Persian Gulf War~* Chronic muscle pain~Exclusion Criteria:~* Regular participation in resistance exercise~* Color blindness~* Claustrophobia~* Medical conditions that could explain the Veteran's pain~* Use of exclusionary drugs 3 weeks prior to testing~* Major depressive disorder with melancholic features~* Substance abuse~* Schizophrenia~* Bipolar disorder

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Resistance exercise training
- Arm 2 (Type: NO_INTERVENTION): Waitlist Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, \>/= 18 years of age~* Treatment with Pegasys according to label and standard clinical practice~* HBeAg negative serologically proven chronic hepatitis B with or without cirrhosis~* Serum alanine aminotransferase (ALT) \> upper limit of normal (ULN) but \</= 10 x ULN~* Hepatitis B Virus (HBV) DNA \>/= 2000 IU/mL~Exclusion Criteria:~* Contraindications to Pegasys as detailed in the label~* Co-infection with hepatitis A, hepatitis C or HIV~* Pregnant or lactating women~* Participants should not receive concomitant therapy with telbivudine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic Hepatitis B Participants (Type: None): Hepatitis B e antigen (HBeAg) chronic hepatitis B (CHB) participants who received treatment with pegylated interferon alfa (peginterferon alfa) according to China labeling and China standard of care and were followed up to 1 year after treatment cessation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathological diagnosis of classical Hodgkin lymphoma~* Failed standard front-line therapy~* Measurable disease of at least 1.5 cm as documented by radiographic technique~* Eastern Cooperative Oncology Group performance status less than or equal to 2~Exclusion Criteria:~* Received prior salvage therapy, including radiotherapy~* Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed 4 weeks prior to first dose of study drug~* Concurrent use of other investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab Vedotin + Bendamustine (Type: EXPERIMENTAL): Brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles by IV infusion and bendamustine 90 mg/m2 on Days 1 and 2 every 3 weeks by IV infusion for up to 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Induction of Labor in Pregnant Women With Prelabor Rupture of Membranes - Oxytocin or Misoprostol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age (36-42 weeks).~* Prelabor rupture of membranes within the last 24hours~* Vertex presentation~Exclusion Criteria:~1. History of medical diseases (HTN, diabetes milletus, systemic lupus erythematosus, cardiac, etc.).~2. Antepartum hemorrhage~3. Chorioamnionitis / prelabor rupture of membranes \>24hours~4. Multiple pregnancy.~5. Abnormal fetal heart rate pattern upon admission~6. Intrauterine growth restriction~7. Fetal malpresentation.~8. Previous uterine scar.~9. Estimated fetal weight more than 4kg.~10. Patients already in labor~11. Contraindication for prostaglandin/oxytocin use (allergy,..)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- misoprostol group (Type: ACTIVE_COMPARATOR): 25µg misoprostol oral tablet every 4 hours with maximum200 µg
- oxytocin group (Type: ACTIVE_COMPARATOR): oxytocin infusion according to ASUMH local protocol: Put 3IU oxytocin (3000mIU) +50ml of normal saline in syringe pump= (60mIU/ml). Commence at 1ml/hour (1mIU/min) for 1/2 hour.~* If contractions inadequate +fetal monitor healthy 2 ml/hour for 1/2 hour.~* If contractions inadequate +fetal monitor healthy 4 ml/hour for 1/2 hour.~* If contractions inadequate +fetal monitor healthy 6 ml/hour for 1/2 hour.~* If contractions inadequate +fetal monitor healthy increase by 2ml/hr. for max. 27ml/hour.~At any point there's fetal or maternal distress (e.g. pathological FHR pattern, antepartum hemorrhage, etc.) the study intervention will be stopped, and the maternal/fetal condition will be managed by cesarean section.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intensive Insulin Treatment and Ischemic Foot Ulcer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Born 1930 or later, Type 1 diabetes appearing at age 30 or earlier and with insulin dependency within 1 year from diagnosis, no known abuse of alcohol or drugs, non-prolipherative retinopathy of any degree present, no previous photocoagulation, normal serum creatinine, unsatsifactory blood glucose control according to the physician in charge of the patients.~Exclusion Criteria:~Any history or ongoing ischemic foot ulcer,or peripheral artery disease,or osteoartropathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Intensified insulin treatment (Type: EXPERIMENTAL): Basal (Monotard) insulin; ones a day Bolus (Actrapid) insulin; thrice a day
- Standard treatment (Type: ACTIVE_COMPARATOR): Mixed Insulin (2-3 times a day)
- Healthy controls (Type: NO_INTERVENTION): These people were solely controls for the iontophoresis method used in the study. With no intervention or follow-up-

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Performance of a New Implant System for Bone Conduction Hearing

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects (18 years or older)~* Subject with conductive or mixed hearing loss in the ear to be implanted. Bone conduction thresholds with pure tone average (PTA4; mean of 0.5, 1, 2 and 4 kHz) of 55 dB HL.~OR Subject with single-sided sensorineural deafness who is a candidate for Baha surgery. Air conduction thresholds with a pure tone average PTA4 of 20 dB HL (mean of 0.5, 1, 2 and 3 kHz) in the good ear OR subject who is indicated for an AC CROS but-for some reason-cannot or will not use an AC CROS (Air Conduction-Contralateral Routing of Signal).~* Signed informed consent~* Previous experience from amplified sound though a non-surgical solution. (For example but not limited to Hearing aid, CROS device, Bone conductional hearing device on headband/ softband)~Exclusion Criteria:~* Uncontrolled diabetes as judged by the investigator.~* Condition that could jeopardise osseointegration and/or wound healing (e.g. osteoporosis, psoriasis, long-term systemic use of corticosteroids) or condition that may have an impact on the outcome of the investigation as judged by the investigator.~* Insufficient bone quality and quantity for implantation of a BI300 Implant.~* Subject that has received radiotherapy in the area of implantation, or is planned for such radiotherapy during the study period~* Use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator~* Unable to follow investigational procedures, e.g. to complete quality of life scales.~* Participation in another clinical investigation with pharmaceutical and/or device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Bone-conduction hearing device (Type: EXPERIMENTAL): The bone-conduction hearing device Osia system allows a direct bone-conduction through an osseointegrated implant. A magnet allows the external Sound Processor to be placed in the correct position over the implanted system including an inner magnet.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~* Individuals with chronic HCV infection~* HCV RNA ≥10\^4 IU/mL at screening~* HCV genotypes 2, 3, 4, 5, or 6~* Cirrhosis determination; a liver biopsy may be required~* Screening laboratory values within defined thresholds~* Use of two contraception methods if female of childbearing potential or sexually active male~Key Exclusion Criteria:~* Pregnant or nursing female~* Current or prior history of hepatic decompensation~* Hepatocellular carcinoma (HCC) or other clinically significant malignancy~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VOX+SOF/VEL 6 wk, TN, without cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
- GS-9857+SOF/VEL 6 wk, TN, with cirrhosis (Type: EXPERIMENTAL): GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
- VOX+SOF/VEL 8 wk, TN, with cirrhosis (Type: EXPERIMENTAL): GS-9857 + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
- VOX+SOF/VEL 8 wk,TE, without cirrhosis (Type: EXPERIMENTAL): GS-9857 + SOF/VEL for 8 weeks (treatment experienced (TE), without cirrhosis)
- VOX+SOF/VEL 12 wk, TE, without cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
- GS-9857+SOF/VEL 8 wk, TE, with cirrhosis (Type: EXPERIMENTAL): GS-9857 + SOF/VEL for 8 weeks (treatment experienced, with cirrhosis)
- VOX+SOF/VEL 12 wk, TE, with cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin Three Year Pediatric Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Heterozygous familial hypercholesterolemia, ages 6-15, LDL greater than 4 mmol/l~Exclusion Criteria:~* Active liver disease or hepatic dysfunction, or persistent elevations of serum transaminases exceeding three times the upper limit of normal (ULN).~Female of childbearing potential who is not using adequate contraceptive measures or any female who is pregnant or breastfeeding. Any female who becomes pregnant during study participation will be immediately discontinued from treatment and counseled appropriately about the in utero exposure.~Known hypersensitivities to HMG-CoA reductase inhibitors

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): All subjects will be treated with atorvastatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Education on Labor Analgesia Options

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Postpartum women ages 18 and older~* Patients who speak and read English or Spanish~* Patients who received our informational pamphlet while pregnant or in labor~* Patients who are able to consent and make medical decisions~* Patients undergoing labor or trial of labor after cesarean delivery~* Patients who undergo cesarean delivery after trial of labor~Exclusion Criteria:~* Patients unable or unwilling to complete questionnaire~* Patients unable to consent or make medical decisions~* Patients less than 18 years of age~* Patients unable to read and speak English or Spanish~* Patients in whom any of the analgesic options were contraindicated~* Patients with a history of an anxiety disorder~* Patients with precipitous labor or late presentation that precluded an analgesic intervention~* Patients with fetal distress that precluded an analgesic intervention~* Patients planned for elective cesarean section.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must have provided written informed consent for the trial.~* Participant must have cryopreserved embryo(s) in trial P06029 (NCT01144416) of which at least one embryo is thawed for use in a subsequent FTET cycle.

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Corifollitropin alfa 150 μg (Type: EXPERIMENTAL): Participants in Base Study P06029 received a single injection of 150 ug corifollitropin alfa on Stimulation Day 1 and daily injections of placebo-recFSH from Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
- recFSH 300 IU (Type: ACTIVE_COMPARATOR): Participants in the reference group in Base Study P06029 received a single injection of placebo for corifollitropin alfa on Stimulation Day 1 and daily injections of 300 IU recFSH on Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/=18 years of age~* chronic lymphocytic leukemia~* active CLL with progressive Binet stage B or C~* ineligible for treatment with fludarabine~* for second line patients, only pretreatment with rituximab and/or chlorambucil is allowed~* EOCG performance status \>/=2~Exclusion Criteria:~* patients who have relapsed within \<12 months of first dose of prior rituximab or chlorambucil first-line therapy~* previous or planned stem cell transplantation~* radioimmunotherapy within 6 months prior to starting study treatment~* transformation to aggressive B-cell malignancy~* any other concurrent anti-cancer therapy, or glucocorticoid \>/=20mg daily prednisolone or equivalent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~To be eligible, volunteers must be 18 to 45 years old, who~1. are not participating in or plan to participate in another research protocol during the next three months;~2. have not been vaccinated against typhoid fever or had typhoid fever within the last 5 years;~3. are not regularly taking a prescription drug for chronic medical condition;~4. have no history of allergy to fruit or fruit pectin;~5. are not pregnant or intend to become pregnant during the study period of 6 months;~6. Whose HIV, HBsAg and HCV tests must be found negative and laboratory tests of liver function, blood chemistry, complete blood count and urine must show no clinically significant abnormality or pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete